ProNAi Therapeutics Inc. (NASDAQ:DNAI) shares were down 3.7% during mid-day trading on Tuesday . The stock traded as low as $2.06 and last traded at $2.09, with a volume of 927,020 shares. The stock had previously closed at $2.17.

A number of analysts recently commented on the company. Zacks Investment Research lowered ProNAi Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, May 4th. Wedbush reaffirmed an “outperform” rating and issued a $36.00 price target on shares of ProNAi Therapeutics in a research note on Friday, May 27th. Jefferies Group reaffirmed a “buy” rating on shares of ProNAi Therapeutics in a research note on Sunday, May 29th. Finally, SunTrust Banks Inc. lowered ProNAi Therapeutics from a “buy” rating to a “neutral” rating and dropped their price target for the stock from $25.00 to $4.00 in a research note on Monday, June 6th. Four research analysts have rated the stock with a hold rating and one has given a buy rating to the company. The company presently has a consensus rating of “Hold” and a consensus target price of $17.35.

The firm’s market capitalization is $61.40 million. The company has a 50 day moving average price of $2.39 and a 200 day moving average price of $5.93.

ProNAi Therapeutics (NASDAQ:DNAI) last issued its quarterly earnings data on Tuesday, May 10th. The company reported ($0.35) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.42) by $0.07. On average, equities research analysts expect that ProNAi Therapeutics Inc. will post ($1.33) EPS for the current fiscal year.

An institutional investor recently bought a new position in ProNAi Therapeutics stock. Jennison Associates acquired a new stake in ProNAi Therapeutics Inc. (NASDAQ:DNAI) during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 150,381 shares of the company’s stock, valued at approximately $3,086,000. Jennison Associates owned 0.50% of ProNAi Therapeutics as of its most recent SEC filing.

ProNAi Therapeutics, Inc is a clinical-stage oncology company. The Company is engaged in business of researching, developing and commercializing therapies for the treatment of patients with cancer and hematological diseases based on its deoxyribonucleic acid interference (DNAi) technology platform. Its lead product candidate includes PNT2258, which targets cancers that overexpress B-cell lymphoma 2 (BCL2), an oncogene known to be dysregulated in various types of cancer.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.